Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports

Wegovy was found to cut the risk of serious heart events by 20%—Novo Nordisk has now asked the U.S. FDA to reflect the heart benefits in the drug's label.

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk's CEO doesn't like proposed new EU rules that would cut the period for which drugmakers enjoy exclusivity for their products from 10 years to eight years.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Novo Nordisk isn’t alone: Sales of Wegovy rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze

Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.

Novo Crushes Forecasts As Sales Of Weight-Loss Drug Rocket Eightfold

Novo Nordisk stock gapped up Thursday after reporting sweeping growth for weight-loss drug Wegovy, though Ozempic sales missed.

Investors Business Daily

Novo Nordisk gives foodmakers $900 million reason to worry

Sales would have been higher if not for a shortfall following surging demand.

Sales soar at Danish firm behind weight-loss drug semaglutide

Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company

The Guardian - UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?

Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?

The good times keep rolling for Novo Nordisk and its weight-loss drugs. But it's bad news for some medical device stocks.

Investors Business Daily

Stock Market Rallies, Hits Resistance; Novo Nordisk, JPMorgan, Exxon In Focus: Weekly Review

Stock Market Rallies, Hits Resistance; Novo Nordisk, JPMorgan, Exxon In Focus: Weekly Review

The major indexes rallied for the week, but hit resistance at key levels amid weak stock market breadth. Novo Nordisk, JPMorgan, Exxon were in focus.

Investors Business Daily

Why Novo's Good News For Ozempic Slammed Dialysis Stocks DaVita And Fresenius

Why Novo's Good News For Ozempic Slammed Dialysis Stocks DaVita And Fresenius

Novo Nordisk stock popped Wednesday after the company hinted Ozempic showed early promise in kidney disease treatment.

Investors Business Daily

Wall Street is now betting against restaurant stocks because of Novo Nordisk’s Ozempic and high interest rates

Wall Street is now betting against restaurant stocks because of Novo Nordisk’s Ozempic and high interest rates

Short positions on companies such as McDonald’s and Starbucks have increased in the last month, and weight loss drugs are part of the reason why.

Weight-loss drugs like Ozempic have so much promise a major bank is telling investors to short junk food stocks

Weight-loss drugs like Ozempic have so much promise a major bank is telling investors to short junk food stocks

Barclays strategists expect "disruption into a number of industries," thanks to drugs like Novo Nordisk's Ozempic and Wegovy.

Novo Nordisk Stock Skids After FDA Inspection Turns Up Problematic Bacteria In Key Plant

Novo Nordisk Stock Skids After FDA Inspection Turns Up Problematic Bacteria In Key Plant

Novo Nordisk found "objectionable" bacteria in several batches of semaglutide, according to an FDA report. Novo Nordisk stock fell Thursday.

Investors Business Daily

Novo Nordisk Dives After FDA Reportedly Finds 'Objectionable' Conditions At A Key Wegovy Plant

Novo Nordisk Dives After FDA Reportedly Finds 'Objectionable' Conditions At A Key Wegovy Plant

Novo Nordisk stock skidded Monday on reports an inspection turned up "objectionable conditions" at a diabetes and weight-loss drugs manufacturing plant.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Novo Nordisk beats LVMH to become Europe’s most valuable company after it takes its ‘miracle’ weight loss drug Wegovy to the U.K.

The Danish pharma giant overtook French luxury conglomerate LVMH as the most valuable European company, which held the title since 2021.

Investors Business Daily

How Novo Nordisk, A Top 1% Stock, Just Hit Another Bull's-eye In Obesity Treatment

Novo Nordisk said Friday its obesity treatment, Wegovy, reduced heart-failure symptoms. But Novo Nordisk stock remained flat.

Investors Business Daily

Why This Nugget Of Bad Weight-Loss News Isn't Weighing On Lilly, Novo

Prescriptions of weight-loss and diabetes drugs have rocketed this year, giving Novo Nordisk stock and Eli Lilly stock more room to run.

Investors Business Daily

Novo Reverses Obesity-Related Winning Streak, Diving On Light Sales

Novo is restricting some doses of Wegovy in the U.S., the company said Thursday. Novo Nordisk stock fell on light second-quarter sales.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?

Investors Business Daily

Why The Weight-Loss Bonanza Catapulted Lilly And Novo, But Hammered Dexcom And Others

Novo Nordisk stock surged Tuesday after the firm said its weight-loss drug reduced the risk of cardiovascular events.

Novo Nordisk developed Ozempic and started a weight-loss revolution. Its next moonshot is eliminating obesity altogether

Novo’s Ozepmic and Wegovy drugs have altered the mission of the 100-year-old Danish pharma firm best known—until now—for insulin.

Investors Business Daily

AI Stocks Lead These 5 Names Near Buy Points

Artificial intelligence stocks including chipmaker Marvell Technology (MRVL), Arista Networks (ANET) and Synopsys (SNPS), which has launched AI-based chip-design tools, lead this weekend's watch list of five stocks near buy points. In addition to MRVL, ANET and SNPS stock, weight-loss drug leader Novo Nordisk (NVO) and Heico (HEI), a military…

Investors Business Daily

IBD Stock Of The Day Novo Nordisk, A Weight-Loss Kingpin, Just Retook Its 50-Day Line

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

Investors Business Daily

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

Investors Business Daily

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

People

Elizabeth Anderson

Lars Fruergaard Jørgensen

Ihor Dusaniwsky

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Bank of America

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

294,198 stories

118,817 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play